A sensitive ultra‐performance liquid chromatography‐tandem mass spectrometry method for the simultaneous quantification of assay and trace‐level genotoxic tosylate analogs (methyl and ethyl) in empagliflozin and its tablet dosage forms

Isolation, identification, structural elucidation, and toxicity prediction using (Q)-SAR models of two degradants: AQbD-driven LC method to determine the Roxadustat impurities

(2023) Srinivas Nakka et al.   Talanta Open

Development and validation of liquid chromatography method for determination of Ibrutinib in finished dosage forms using quality by design approach

(2022) Naresh Konduru et al.   Separation Science Plus

Implementation of analytical quality by design and green chemistry principles to develop an ultra-high performance liquid chromatography method for the determination of Fluocinolone Acetonide impurities from its drug substance and topical oil formulations

(2022) Siva Krishna Muchakayala et al.   JOURNAL OF CHROMATOGRAPHY A

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction

(2022) Javed Butler et al.   CIRCULATION

AQbD based green UPLC method to determine mycophenolate mofetil impurities and Identification of degradation products by QToF LCMS

(2022) Siva Krishna Muchakayala et al.   Scientific Reports

An effective ultra‐performance liquid chromatography and derivatization method for the quantification of potential genotoxic impurity Hydrazine in Gliclazide and its formulation – Robustness study by the design of experiments

(2022) Srinivas Nakka et al.   Separation Science Plus

Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial

(2021) Michael E. Nassif et al.   CIRCULATION

Isolation and characterization of novel process-related impurities in empagliflozin

(2021) Yanqing Chen et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Development and validation of an analytical method for quantitative determination of three potentially genotoxic impurities in vildagliptin drug material using HPLC ‐MS

(2021) Bashar Al‐Sabti et al.   JOURNAL OF SEPARATION SCIENCE

Determination of progesterone (steroid drug) in the semi ‐ solid dosage form (vaginal gel) using a stability ‐ indicating method by RP‐HPLC/PDA detector

(2021) Naresh Konduru et al.   BIOMEDICAL CHROMATOGRAPHY

Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial

(2021) Milton Packer et al.   CIRCULATION

Validation of a novel UPLC-MS/MS method for estimation of metformin and empagliflozin simultaneously in human plasma using freezing lipid precipitation approach and its application to pharmacokinetic study

(2021) M.N. Abou-Omar et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

(2021) Javed Butler et al.   EUROPEAN HEART JOURNAL

Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine

(2020) Annemarie B. van der Aart-van der Beek et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

(2020) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Determination of empagliflozin in the presence of its organic impurities and identification of two degradation products using UHPLC-QTOF/MS

(2020) Joanna Wittckind Manoel et al.   MICROCHEMICAL JOURNAL

Structural characterization of forced degradation products of empagliflozin by high resolution mass spectrometry

(2019) Prakash Niguram et al.   JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES

Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography–mass spectrometry and application to pharmacokinetics

(2019) Tejas Wattamwar et al.   EUROPEAN JOURNAL OF MASS SPECTROMETRY

Empagliflozin: A Review in Type 2 Diabetes

(2018) James E. Frampton   DRUGS

Identification, isolation, characterization, and UHPLC quantification of potential genotoxic impurities in linagliptin

(2018) Yiwen Huang et al.   JOURNAL OF SEPARATION SCIENCE

LC–MS/MS Determination of Empagliflozin and Metformin

(2017) Bassam M. Ayoub et al.   JOURNAL OF CHROMATOGRAPHIC SCIENCE

A practical application of two in silico systems for identification of potentially mutagenic impurities

(2015) Nigel Greene et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2014) André J. Scheen   DRUGS

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

(2014) Michael Nauck   Drug Design Development and Therapy